Full Text View
Tabular View
Study Results
Related Studies
The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy
This study has been completed.
Study NCT00694161   Information provided by Pfizer

First Received on June 6, 2008.   Last Updated on January 4, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cardiomyopathy
Additional conditions recognized in this trial
Amyloidosis
Cardiomyopathies
More general conditions related to this trial
Cardiovascular Diseases
Heart Diseases
Metabolic Diseases
Proteostasis Deficiencies
Interventions listed in this trial
Fx-1006A
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services